The pharma giant also issued an upbeat forecast for 2026
Eli Lilly And Co (NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forecast for 2026. The company attributed the strong showing to Zepbound and Mounjaro sales.
LLY is today pacing for for its best day since October as it tests overhead pressure at the $1,100 level, which has kept price action in check since a Jan. 8, record high of $1,113.98. The equity is bouncing off the rising 80-day moving average, and sports a 30.3% year-over-yead lead.
Drilling down to today's options activity, 15,000 calls and 14,000 puts have already exchanged hands, which is double the volume typically seen at this point. The most popular contract by far is the March 940-strike put, where new positions are currently being sold to open.
Short-term options traders have been much more bearish than usual. This is per the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.06 that ranks in the 94th percentile of its annual range.